Mode
Text Size
Log in / Sign up
N/A N=21

Donor Human Milk in Neonatal Abstinence Syndrome

Neonatal Abstinence Syndrome

Enrolled (actual)
21
Serious AEs
0.0%
Results posted
Apr 2019
Primary outcome: Primary: Percentage of Infants Achieving a GI Subscore >2 Over the Study Period — 39; 61 Percentage of participants — p=0.001

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
donor human milk (Dietary_supplement)
Age
Pediatric · 0+ yrs
Sex
All
Sponsor
Neolac Inc dba Medolac Laboratories
Primary completion
Aug 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Infants Achieving a GI Subscore >2 Over the Study Period
39; 61 0.001 sig
SECONDARY
Weight Change at 2 Weeks
19.1; 20.5 0.875
SECONDARY
Head Circumference Change at 2 Weeks
0.4; 0.6 0.025 sig

Summary

This study is designed to develop pilot data on the acceptability and benefit of donor human milk for infants undergoing pharmacologic treatment for NAS. Specifically, gastrointestinal (GI) sub-scores, as well as total scores, will be compared between infants historically fed formula and those enrolled in a 2-week donor human milk study period. Purpose of study: to test the following null hypothesis: Infants with a diagnosis of neonatal abstinence syndrome (NAS) due to in-utero exposure to opiates, fed donor human milk, will have similar GI/feeding sub-scores of the Finnegan scoring tool when compared to (historic) infants fed formula. A rejection of the null hypothesis will be used to design a randomized trial of donor human milk in infants with NAS.

Eligibility Criteria

Inclusion Criteria

  • Term infants (>37 completed weeks) with a diagnosis of NAS, due to maternal use of opiates (only)
  • Infants will have had moderate to severe NAS symptoms (Finnegan scores >8) that required pharmacologic therapy but have been stabilized (captured) on oral morphine (Finnegan scores less than 8 for 24 hours)
  • Breastfeeding is contraindicated or the mother has chosen formula feeding for her baby

Exclusion Criteria

  • Preterm infants (<37 completed weeks at birth)
  • Infants with intrauterine growth restriction (BW <10th percentile for gestational age)
  • Mother is providing her own milk
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02182973). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search